Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

NCT01605162 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Wild Type BRAF Stage IV Melanoma
Unresectable Stage III Melanoma

Interventions

DRUG: TMZ
DRUG: E7016

Sponsor

Eisai Inc.